Connect with us


Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference




SOUTH SAN FRANCISCO, CA, Sept. 20, 2022 (GLOBE NEWSWIRE) – Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotech company creating next-generation cellular and genetic therapies using its own gene, the Circuit platform announced today that Co-Founder and CEO, Tim Low, Chief Financial Officer, Deb Nobleman, and CMDO, Kanya Rajangam will participate in the Fireside Talk at the 6th Annual Chardin Conference on Genetic Medicine on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also participate in a panel on gene regulation on Tuesday, October 4, 2022 at 9:30 AM ET.

The live webcast of Fireside chat can be accessed through Events and Presentations A section of the Senti Bio website is under the Investors tab and will be available for 120 days after the presentation.

About Senti Bio
Our mission is to create a new generation of smarter drugs that outperform complex diseases using new and unprecedented approaches. To achieve this, we are building a synthetic biology platform that may enable us to program the next generation of cellular and genetic therapies with what we refer to as genetic circuits. Constructed from novel and proprietary combinations of DNA sequences, these genetic circuits are designed to reprogram cells with biological logic to sense input, account for decisions and respond to their cellular environments. We aim to design genetic circuits to improve the intelligence of cellular and genetic therapies in order to enhance their therapeutic efficacy, accuracy and tolerability against a wide range of diseases that are not easily treated by conventional drugs.


Our synthetic biology platform uses placebo antigen receptor (CAR-NK) natural killer cells, equipped with Gene Circuit technologies, to target both liquid and solid tumor markers. Our lead development candidate is SENTI-202 for the treatment of acute myeloid leukemia (AML). Additional CAR-NK programs include SENTI-301 for the treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the treatment of colorectal cancer (CRC). We have also demonstrated the breadth of our genetic circuits in other modalities and diseases beyond oncology and have implemented partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.

Availability of other information about Senti Biosciences, Inc.
For more information, please visit the Senti Bio website or follow Senti Bio on Twitter (SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our corporate website (, including, but not limited to, company disclosures, investor presentations and frequently asked questions, Securities and Exchange Commission filings, press releases, transcripts of calls Public collegiate and broadcast transcripts across the web, as well as on Twitter and LinkedIn. Information we post on our website, Twitter or LinkedIn may be considered material. As a result, we encourage investors, the media, and other interested parties to review the information we publish there on a regular basis. The contents of our website or social media may not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.

You can find more information at
Follow us on Linkedin: Centi Biological Sciences
Follow us on Twitter: Tweet embed


Click to comment

Leave a Reply

Your email address will not be published.



Copyright © 2022 Theme by The Nitesh Arya.